Paradigm Biopharmaceuticals (ASX:PAR) Capital Expenditure : A$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Paradigm Biopharmaceuticals's cash flow for capital expenditures for the six months ended in Dec. 2024 was A$0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

Paradigm Biopharmaceuticals Capital Expenditure Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Capital Expenditure Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Capital Expenditure

Get a 7-Day Free Trial

-0.13

-0.03

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Capital Expenditure	Get a 7-Day Free Trial														-	-	-	-	-

Paradigm Biopharmaceuticals Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Paradigm Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

PBIGF:USA P86:Germany

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.